Literature DB >> 25949722

The prevalence of comorbidities among people living with HIV in Brent: a diverse London Borough.

Ava Lorenc1, Piriyankan Ananthavarathan2, James Lorigan, Mohamade Jowata3, Gary Brook4, Ricky Banarsee5.   

Abstract

Background HIV has changed from a rapidly deteriorating illness to a complex chronic disease, with increasing incidences of comorbidity, including cancer, and liver, lung and cardiovascular diseases. North West London has 6719 individuals living with the human immunodeficiency virus (HIV), 873 of whom reside in the London Borough of Brent. Traditionally, commissioning services have focused on HIV therapy alone without considering how comorbidity affects treatment outcome and total service costs. Setting The setting for the study was NHS Brent Primary Care Trust, London UK. Question What associated comorbidities are present in people in Brent (London, UK) living with HIV, and how common are they? Methods A point-prevalence audit of retrospective data was conducted on all HIV-positive patients in Brent (financial year 2011/12). Data were collected from genito-urinary medicine (GUM) services, community services and general practitioners (GPs) on HIV diagnosis, patient demographics and past/current comorbidities: hepatitis B and C, cardiovascular disease, diabetes and mental health disorders. Results This study identified that 29% of people living with HIV/AIDS (PLWHA) in Brent have at least one comorbidity. The most common was hepatitis, followed by mental health disorders and cardiovascular disease (CVD). Comorbidity was more likely in older male patients (in particular CVD and diabetes) and White patients (except for diabetes which was more common in Asian groups). Discussion/Conclusion Many PLWHA in Brent suffer from a number of other conditions, which appear largely independent of HIV. Findings confirm the need to treat HIV as a long-term condition, including patient education, empowerment and encouraging self-management. The multi-morbidity of many PLWHA suggests a role for both primary care and collaborative, holistic, patient-centred and individualised healthcare. Service providers and commissioners need to consider comorbidities in their treatment of and provision of services for PLWHA. This study also highlighted the need for services to address limitations of their data collection systems.

Entities:  

Keywords:  AIDS; HIV; clinical audit; comorbidity

Year:  2014        PMID: 25949722      PMCID: PMC4238727          DOI: 10.1080/17571472.2014.11493422

Source DB:  PubMed          Journal:  London J Prim Care (Abingdon)        ISSN: 1757-1472


  35 in total

1.  General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era.

Authors:  A M Kilbourne; A C Justice; L Rabeneck; M Rodriguez-Barradas; S Weissman
Journal:  J Clin Epidemiol       Date:  2001-12       Impact factor: 6.437

2.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

3.  Prioritizing primary care in HIV: comorbidity, toxicity, and demography.

Authors:  Amy C Justice
Journal:  Top HIV Med       Date:  2006 Dec-2007 Jan

Review 4.  A review of the literature on HIV infection and schizophrenia: implications for research, policy and clinical practice.

Authors:  Richard Gray; Elizabeth Brewin; James Noak; Janelle Wyke-Joseph; Babita Sonik
Journal:  J Psychiatr Ment Health Nurs       Date:  2002-08       Impact factor: 2.952

5.  Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients.

Authors:  Eugènia Mariné-Barjoan; Marie-Christine Saint-Paul; Christian Pradier; Sylvie Chaillou; Rodolphe Anty; Jean-François Michiels; Christophe Sattonnet; Denis Ouzan; Pierre Dellamonica; Albert Tran
Journal:  AIDS       Date:  2004-11-05       Impact factor: 4.177

6.  Changes in the clinical epidemiology of HIV infection in the United States: implications for the clinician.

Authors:  Kate Buchacz; Maria Rangel; Rachel Blacher; John T Brooks
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

7.  The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes.

Authors:  J Turner; L Bansi; R Gilson; B Gazzard; J Walsh; D Pillay; C Orkin; A Phillips; P Easterbrook; M Johnson; K Porter; A Schwenk; T Hill; C Leen; J Anderson; M Fisher; C Sabin
Journal:  J Viral Hepat       Date:  2009-10-13       Impact factor: 3.728

8.  Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity?

Authors:  Joseph L Goulet; Shawn L Fultz; David Rimland; Adeel Butt; Cynthia Gibert; Maria Rodriguez-Barradas; Kendall Bryant; Amy C Justice
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079

9.  Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services.

Authors:  Laurie Sylla; R Douglas Bruce; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2007-05-10

Review 10.  Evidence based cardiology: psychosocial factors in the aetiology and prognosis of coronary heart disease. Systematic review of prospective cohort studies.

Authors:  H Hemingway; M Marmot
Journal:  BMJ       Date:  1999-05-29
View more
  16 in total

1.  Differential contribution of chronic binge alcohol and antiretroviral therapy to metabolic dysregulation in SIV-infected male macaques.

Authors:  Stephen M Ford; Liz Simon Peter; Paul Berner; Garth Cook; Curtis Vande Stouwe; Jason Dufour; Gregory Bagby; Steve Nelson; Patricia E Molina
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-07-24       Impact factor: 4.310

2.  Deprenyl reduces inflammation during acute SIV infection.

Authors:  K M Emanuel; K Runner; Z D Brodnik; B M Morsey; B G Lamberty; H S Johnson; A Acharya; S N Byrareddy; R A España; H S Fox; P J Gaskill
Journal:  iScience       Date:  2022-04-06

3.  Prevalence, healthcare costs and management of non-communicable diseases in people living with human immunodeficiency virus: A scoping review.

Authors:  Laston Gonah; Indres Moodley; Khumbulani Hlongwana
Journal:  Afr J Prim Health Care Fam Med       Date:  2020-10-19

4.  Statistical models for analyzing count data: predictors of length of stay among HIV patients in Portugal using a multilevel model.

Authors:  Ahmed Nabil Shaaban; Bárbara Peleteiro; Maria Rosario O Martins
Journal:  BMC Health Serv Res       Date:  2021-04-21       Impact factor: 2.655

5.  The HIV-Tat protein interacts with Sp3 transcription factor and inhibits its binding to a distal site of the sod2 promoter in human pulmonary artery endothelial cells.

Authors:  Terrin L Manes; Ari Simenauer; Jason L Geohring; Juliana Flemming; Michael Brehm; Adela Cota-Gomez
Journal:  Free Radic Biol Med       Date:  2019-12-19       Impact factor: 7.376

6.  Higher Comorbidity Burden Predicts Worsening Neurocognitive Trajectories in People with Human Immunodeficiency Virus.

Authors:  Ronald J Ellis; Emily Paolillo; Rowan Saloner; Robert K Heaton
Journal:  Clin Infect Dis       Date:  2022-04-28       Impact factor: 20.999

7.  CLINICAL PRESENTATION OF HIV-INFECTED PATIENTS IN A PSYCHIATRIC HOSPITAL IN SOUTH AFRICA.

Authors:  Shren Chetty; Kalai Naidu
Journal:  Afr J Infect Dis       Date:  2018-06-18

8.  Chronic Diseases Multimorbidity among Adult People Living with HIV at Hawassa University Comprehensive Specialized Hospital, Southern Ethiopia.

Authors:  Endrias Markos Woldesemayat
Journal:  Int J Chronic Dis       Date:  2020-01-22

9.  Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database.

Authors:  C Okoli; A Schwenk; M Radford; M Myland; S Taylor; A Darley; J Barnes; A Fox; F Grimson; I Reeves; S Munshi; A Croucher; N Boxall; P Benn; A Paice; J van Wyk; S Khoo
Journal:  HIV Med       Date:  2020-07-15       Impact factor: 3.180

10.  Prevalence of diabetes mellitus and hypertension in people living with human immunodeficiency virus on antiretroviral therapy in Gweru district, Zimbabwe.

Authors:  Laston Gonah; Indres Moodley; Khumbulani Hlongwana
Journal:  Afr J Prim Health Care Fam Med       Date:  2020-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.